Applied Genetic Technologies Corp. (NASDAQ:AGTC) shares were up 4.5% during trading on Wednesday . The stock traded as high as $15.58 and last traded at $15.38, with a volume of 53,496 shares traded. The stock had previously closed at $14.72.

Several research analysts recently commented on AGTC shares. Janney Montgomery Scott started coverage on Applied Genetic Technologies Corp. in a research report on Friday, March 18th. They issued a “buy” rating and a $23.00 price target for the company. BMO Capital Markets began coverage on shares of Applied Genetic Technologies Corp. in a research note on Monday, April 11th. They issued an “outperform” rating and a $25.00 price objective for the company. Zacks Investment Research downgraded shares of Applied Genetic Technologies Corp. from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 12th. Roth Capital reissued a “buy” rating on shares of Applied Genetic Technologies Corp. in a research note on Monday, April 25th. Finally, Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Applied Genetic Technologies Corp. in a research note on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $26.00.

The firm has a 50-day moving average of $15.42 and a 200-day moving average of $15.45. The company’s market capitalization is $277.89 million.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last issued its earnings results on Monday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.06. The firm earned $12 million during the quarter, compared to the consensus estimate of $12.98 million. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. The business’s quarterly revenue was up 4125.4% compared to the same quarter last year. Analysts forecast that Applied Genetic Technologies Corp. will post ($0.16) earnings per share for the current year.

Several hedge funds have recently modified their holdings of AGTC. Jennison Associates LLC raised its stake in shares of Applied Genetic Technologies Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 677,610 shares of the company’s stock valued at $13,823,000 after buying an additional 3,248 shares during the last quarter. Globeflex Capital L P purchased a new stake in shares of Applied Genetic Technologies Corp. during the fourth quarter valued at about $1,189,000. CAM Group Holding A S purchased a new stake in shares of Applied Genetic Technologies Corp. during the fourth quarter valued at about $1,428,000. Russell Frank Co purchased a new stake in shares of Applied Genetic Technologies Corp. during the fourth quarter valued at about $1,541,000. Finally, Numeric Investors LLC raised its stake in shares of Applied Genetic Technologies Corp. by 984.6% in the fourth quarter. Numeric Investors LLC now owns 226,689 shares of the company’s stock valued at $4,624,000 after buying an additional 205,789 shares during the last quarter.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.